(0.30%) 5 115.49 points
(0.30%) 38 356 points
(0.36%) 15 985 points
(-0.97%) $83.04
(5.36%) $2.03
(0.30%) $2 354.30
(0.56%) $27.69
(4.31%) $961.80
(-0.27%) $0.932
(-0.47%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.73%
Live Chart Being Loaded With Signals
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs...
Stats | |
---|---|
本日の出来高 | 50 191.00 |
平均出来高 | 10 954.00 |
時価総額 | 534.69M |
EPS | $0 ( 2024-03-20 ) |
次の収益日 | ( $0.770 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.93 |
ATR14 | $0.0300 (0.39%) |
ボリューム 相関
Valneva SE 相関 - 通貨/商品
Valneva SE 財務諸表
Annual | 2023 |
収益: | $153.71M |
総利益: | $48.54M (31.58 %) |
EPS: | $-0.730 |
FY | 2023 |
収益: | $153.71M |
総利益: | $48.54M (31.58 %) |
EPS: | $-0.730 |
FY | 2022 |
収益: | $361.30M |
総利益: | $36.86M (10.20 %) |
EPS: | $-1.240 |
FY | 2021 |
収益: | $348.09M |
総利益: | $160.17M (46.01 %) |
EPS: | $-0.700 |
Financial Reports:
No articles found.
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。